The approval of the prostate-specific membrane antigen (PSMA) PET scan for prostate cancer staging in 2020 and the approval of Lutetium Lu177 vivpivotide tetraxetan (Lu177) for treating PSMA PET-positive mCRPC in 2022 have opened up tremendous new opportunities for prostate cancer developmental therapeutics. This evidence concerns the gene FOLH1 and prostate carcinoma.